+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

France Bladder Cancer Market 2020-2026

  • ID: 5148071
  • Report
  • August 2020
  • Region: France
  • Orion Market Research Private Limited
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche AG
  • MORE
France Bladder Cancer Market Size, Share & Trends Analysis Report by Cancer Type (Transitional Cell Bladder Cancer/ Urothelial Carcinoma, Squamous Cell Bladder Cancer, Adenocarcinoma, and Other), by Diagnosis (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (IVP), and Others), and by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Other) and Forecast, 2020-2026.

France bladder cancer market is estimated to grow considerably, at a CAGR of around 9.7% during the forecast period. France is one of the leading economies and technologically advanced countries in Europe. France has a quality healthcare system and favorable government policies which is augmenting the growth of the market in France. France has more doctors as compared to UK which means greater accessibility to healthcare. However, the healthcare system of France is very expensive and there are issues in reimbursement policies. The number of new cases associated with bladder cancer is less than that of other economies of the region. Bladder cancer cases accounted for nearly 3.6% of the total cases registered in 2018. In 2018, the total number of new cases of cancer was recorded to be 455,618 out of which 16,282 cases were registered for bladder cancer. Furthermore, Bladder cancer cases were registered more for men as compared to women.

France bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy. There are several companies, such as Nucleix, Ltd. that have introduced biomarkers for the diagnosis of bladder cancer. The high accuracy and speedy diagnosis claim to be a beneficiary factor of the biomarkers that are involved in its increasing adoption for the diagnosis of bladder cancer.

The companies which are contributing to the growth of France bladder cancer market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, Sanofi SA, and Pfizer, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.

Research Methodology:

The market study of France bladder cancer market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • White papers, research-papers, and news blogs.
  • Company websites and their product catalog.
The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.

Market Segmentation:

1. France Bladder Cancer Market Research and Analysis by Cancer Type
2. France Bladder Cancer Market Research and Analysis by Diagnosis
3. France Bladder Cancer Market Research and Analysis by Treatment

The Report Covers:
  • Comprehensive research methodology of the France bladder cancer market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the France bladder cancer market.
  • Insights about market determinants which are stimulating the France bladder cancer market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche AG
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. France Bladder Cancer Market by Cancer Type
5.1.1. Transitional Cell Bladder Cancer/ Urothelial Carcinoma
5.1.2. Squamous Cell Bladder Cancer
5.1.3. Adenocarcinoma
5.1.4. Others (Sarcomas, Carcinoma in Situ)
5.2. France Bladder Cancer Market by Diagnosis
5.2.1. Cystoscopy
5.2.2. Biopsy
5.2.3. Urinalysis
5.2.4. Urine Cytology
5.2.5. Intravenous Pyelogram (IVP)
5.2.6. Others (Biomarkers)
5.3. France Bladder Cancer Market by Treatment
5.3.1. Surgery
5.3.2. Chemotherapy
5.3.3. Immunotherapy
5.3.4. Radiation Therapy
5.3.5. Others (Targeted Therapy)

6. Company Profiles
6.1. Astellas Pharma Inc.
6.2. AstraZeneca PLC
6.3. Bayer AG
6.4. Bristol-Myers Squibb Co.
6.5. Eli Lilly and Co.
6.6. F. Hoffmann-La Roche AG
6.7. GlaxoSmithKline Plc
6.8. Johnson & Johnson Services, Inc.
6.9. Merck KGaA
6.10. Pfizer Inc.
6.11. Sanofi SA
6.12. Sysmex Corp.
Note: Product cover images may vary from those shown
3 of 3
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Pfizer Inc.
  • Sanofi SA
  • Sysmex Corp.
Note: Product cover images may vary from those shown
Adroll
adroll